摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-4-(3-methoxy-carbonyl-2-quinolin-3-yl-propyl)piperidine-1-carboxylic acid tert-butyl ester | 1149753-96-7

中文名称
——
中文别名
——
英文名称
(R)-4-(3-methoxy-carbonyl-2-quinolin-3-yl-propyl)piperidine-1-carboxylic acid tert-butyl ester
英文别名
tert-butyl 4-[(2R)-4-methoxy-4-oxo-2-quinolin-3-ylbutyl]piperidine-1-carboxylate
(R)-4-(3-methoxy-carbonyl-2-quinolin-3-yl-propyl)piperidine-1-carboxylic acid tert-butyl ester化学式
CAS
1149753-96-7
化学式
C24H32N2O4
mdl
——
分子量
412.529
InChiKey
XDGLIEJJVPSXHD-LJQANCHMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    532.6±25.0 °C(predicted)
  • 密度:
    1.133±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    30
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    68.7
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-(3-methoxycarbonyl-2-quinolin-3-ylallyl)piperidine-1-carboxylic acid tert-butyl ester 在 (R)-N-diphenylphosphino-N-[(R)-1-phenylethyl]-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine 、 chlorobis(ethylene)rhodium(I) dimer 氢气 作用下, 以 1,2-二氯乙烷 为溶剂, 20.0~50.0 ℃ 、2.58 MPa 条件下, 反应 18.0h, 以90%的产率得到
    参考文献:
    名称:
    Enantioselective process for preparing a substituted alkanoic acid
    摘要:
    本发明涉及一种用于对手性选择性地制备替代哌啶烷基酸整合素拮抗剂化合物的方法。
    公开号:
    US20090124804A1
点击查看最新优质反应信息

文献信息

  • Suzuki−Miyaura Approach to JNJ-26076713, an Orally Active Tetrahydroquinoline-Containing α<sub>V</sub>β<sub>3</sub>/α<sub>V</sub>β<sub>5</sub> Integrin Antagonist. Enantioselective Synthesis and Stereochemical Studies
    作者:William A. Kinney、Christopher A. Teleha、Andrew S. Thompson、Maria Newport、Ryan Hansen、Scott Ballentine、Shyamali Ghosh、Andrew Mahan、Gabriela Grasa、Antonio Zanotti-Gerosa、Jules Dingenen、Carsten Schubert、Yong Zhou、Gregory C. Leo、David F. McComsey、Rosemary J. Santulli、Bruce E. Maryanoff
    DOI:10.1021/jo702551t
    日期:2008.3.1
    An improved scale-up synthesis was required for the alpha(V)beta(3)/alpha(V)beta(5) integrin antagonist 1, which had demonstrated oral efficacy in eye disease models of angiogenesis and vascular permeability. A stereodefined, quinoline-substituted, unsaturated ester was conveniently prepared by a Suzuki-Miyaura coupling to facilitate exploration of multiple methods of asymmetric reduction. The catalytic chiral hydrogenation of the corresponding unsaturated acid (Z-5b) with a ruthenium-based metal precursor and the (R)-XylPhanePhos ligand proved particularly efficient and economical. The resulting (3S)-quinoline-containing intermediate was reduced to an equal mixture of tetrahydroquinoline diastereomers. The undesired diastereomer could be recycled to the desired one by an oxidation/reduction protocol. The absolute stereochemistry of 1 was established as 3S,3'S by a combination of X-ray diffraction and chemical means.
  • Synthesis of an αvβ3 integrin antagonist intermediate via asymmetric hydrogenation of an α,β-unsaturated ester with BoPhoz-iridium and BoPhoz-rhodium catalysts
    作者:Antonio Zanotti-Gerosa、William A. Kinney、Gabriela A. Grasa、Jonathan Medlock、Andreas Seger、Shyamali Ghosh、Christopher A. Teleha、Bruce E. Maryanoff
    DOI:10.1016/j.tetasy.2008.03.031
    日期:2008.5
    The enantioselective synthesis of an alpha(v)beta(3) integrin antagonist intermediate was approached via asymmetric hydrogenation of a beta,beta-disubstituted-alpha,beta-unsaturated ester. As a result of the rapid parallel screening of a selection of ligands and catalysts, we found that neutral Me-BoPhoz-rhodium and iridium catalysts effect the required transformation with a high enantioselectivity. Both the activity and selectivity of the catalysts were strongly dependent on the choice of solvent and counter-ion. The addition of iodine modified the iridium catalyst such that the reduction of the 3-substituted quinoline ring took place. (C) 2008 Elsevier Ltd. All rights reserved.
  • Enantioselective process for preparing a substituted alkanoic acid
    申请人:Kinney William A.
    公开号:US20090124804A1
    公开(公告)日:2009-05-14
    The present invention is directed to a process for enantioselectively preparing substituted piperidine alkanoic acid integrin antagonist compounds.
    本发明涉及一种用于对手性选择性地制备替代哌啶烷基酸整合素拮抗剂化合物的方法。
查看更多